In a subject-wise analysis conducted by a committee of scientists at Stanford, University the USA Professor Ahmed Kamal has been listed among the top 2% scientists, globally. The team was headed by Dr John PA Ioannidis. The analyses used citations from Scopus with data assessing scientists for career-long citation impact up until the end of 2019 and for citation impact during the single calendar year.
Prof. Ahmed is also ranked among the top 0.10% Scientists in India with 537 papers publication and with a worldwide subject rank of 83 globally and 2nd in India in the subject of Medicinal and Biomolecular Chemistry.
A database of over 100,000 top scientists of the world was devised by Stanford University scientists based on standardized reference indicators such as information on citations, H-index, co-authorship, and a composite indicator. Each of these scientists was classified into 22 scientific fields and 176 sub-fields. For analyses of the citations and the composite indicators, SCOPUS data which was provided by Elsevier was used with data freeze as on May 6, 2020.
Vice-Chancellor of Jamia Hamdard, Prof Seyed Ehthesham Hasnain hailed Prof Kamal for the honours he has brought for the university. The VC also appreciated the efforts that go In for the research publications which have brought this remarkable achievement for the country.
Prof Kamal primarily focuses on the design and synthesis of gene-targeting compounds as new and novel anti-cancer agents and their targeted performance as prodrugs.
Also Read: Law universities get Bar Council’s consent on conducting a physical examination
He has also researched on New chemical substances for anti-tubercular and antimalarial activity. He has experience in the development of new profitable synthetic methodologies including solid phase, resin bound reagents and chemo-enzymatic strategies that are useful in both basic and applied pharmaceutical chemistry.
Professor Kamal has filed over 368 patents and five of his US patents have been licensed to a pharmaceutical company for their clinical development.